Table 5.

One-way Sensitivity Analyses: Incremental Cost-effectiveness of Breast Cancer Screening of Older Women Under Different Conditions^*

Variable	Incremental Costs per LYS†	Incremental Costs per LYS‡
	Screen Ages 50–79 Years	Screen Lifetime from 50 yrs
Survival/treatment
Current (nonidealized)	$40,629	$98,821
Current and quality-adjusted	$71,756	$114,915
Screening interval annual	$118,762	$301,173
Discount rate 10%	$148,980	$225,968
Incidence rate (risk)
Twice average (high-risk)	$62,842	$112,094
Half average (low-risk)	$195,664	$298,126
Dwell times
Shorter than average	$103,939	$190,788
Longer than average	$155,865	$368,801
Quality-adjusted§	–	–

^*Costs and effects discounted at 3%. All parameters are the same as in the base case except for the one variable noted.

^†Compared to stopping screening at age 70 (i.e., compared to screening from age 50 to 70).

^‡Compared to stopping screening at age 79 (i.e., compared to screening from age 50 to 79).

^§Costs are the same as in the base case using LYS. Quality-adjusted life expectancy for extending screening from age 70 to age 79 results in a loss of life expectancy due to the long lead time relative to absolute improvements in survival and disutility of undergoing cancer treatment and living with the knowledge of cancer over the period from screen detection until death (combination of lead time and extended absolute survival).

LYS, life years saved.